Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
Patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes
Empagliflozin
Combined risk of cardiovascular death or hospitalization for heart failurecomposite
Empagliflozin reduces the composite risk of cardiovascular death or heart failure hospitalization in patients with HFpEF, independent of diabetes status.
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).
Building similarity graph...
Analyzing shared references across papers
Loading...
Stefan D. Anker
Javed Butler
Gerasimos Filippatos
New England Journal of Medicine
Inserm
Heidelberg University
Charité - Universitätsmedizin Berlin
Building similarity graph...
Analyzing shared references across papers
Loading...
Anker et al. (Fri,) reported a other. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.
www.synapsesocial.com/papers/6965117d7269e604acbf68f5 — DOI: https://doi.org/10.1056/nejmoa2107038